Tenapanor Scores FDA Advisory Committee Endorsement
An FDA advisory committee said the benefits of tenapanor for treating hyperphosphatemia in patients on dialysis outweighed its risks as both mono- and combo-therapy.
Source: medscape.com
Stay updated with breaking news from Normalizing Serum. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
An FDA advisory committee said the benefits of tenapanor for treating hyperphosphatemia in patients on dialysis outweighed its risks as both mono- and combo-therapy.